Anti-Caspase-1 antibody [EPR19672],Abcam,AB207802
Anti-Caspase-1 antibody [EPR19672] (ab207802) was developed by Abcam using patented rabbit monoclonal antibody technology and is validated for use in IP, WB in human samples. Anti-Caspase-1 antibody [EPR19672] (ab207802) has been cited over 91 times in peer reviewed journals and is trusted by the scientific community. Abcam's high quality manufacturing and validation processes ensure Anti-Caspase-1 antibody [EPR19672] (ab207802) has high sensitivity and specificity alongside high lot-to-lot consistency and reproducibility. The specificity of Anti-Caspase-1 antibody [EPR19672] (ab207802) has been confirmed by testing in knockout samples. Anti-Caspase-1 antibody [EPR19672] (ab207802) specifically detects Caspase-1 (UniProt ID: P29466; Molecular weight: 20kDa) and is sold in 100 µL and 1 mL selling sizes. Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .
Host
Rabbit
Reactivity
Human
Application
IP, WB
Platform ID
BAB615216492
Abcam
Contact
Tel: +44 (0)1223 696000
Fax: +44 (0)1223 215 215
Email:
Specifications
Scientific Background
Target data Thiol protease involved in a variety of inflammatory processes by proteolytically cleaving other proteins, such as the precursors of the inflammatory cytokines interleukin-1 beta (IL1B) and interleukin 18 (IL18) as well as the pyroptosis inducer Gasdermin-D (GSDMD), into active mature peptides (PubMed : 15326478, PubMed : 15498465, PubMed : 1574116, PubMed : 26375003, PubMed : 32051255, PubMed : 37993714, PubMed : 7876192, PubMed : 9334240). Plays a key role in cell immunity as an inflammatory response initiator : once activated through formation of an inflammasome complex, it initiates a pro-inflammatory response through the cleavage of the two inflammatory cytokines IL1B and IL18, releasing the mature cytokines which are involved in a variety of inflammatory processes (PubMed : 15326478, PubMed : 15498465, PubMed : 1574116, PubMed : 32051255, PubMed : 7876192). Cleaves a tetrapeptide after an Asp residue at position P1 (PubMed : 15498465, PubMed : 1574116, PubMed : 7876192). Also initiates pyroptosis, a programmed lytic cell death pathway, through cleavage of GSDMD (PubMed : 26375003). In contrast to cleavage of interleukin IL1B, recognition and cleavage of GSDMD is not strictly dependent on the consensus cleavage site but depends on an exosite interface on CASP1 that recognizes and binds the Gasdermin-D, C-terminal (GSDMD-CT) part (PubMed : 32051255, PubMed : 32109412, PubMed : 32553275). Cleaves and activates CASP7 in response to bacterial infection, promoting plasma membrane repair (PubMed : 22464733). Upon inflammasome activation, during DNA virus infection but not RNA virus challenge, controls antiviral immunity through the cleavage of CGAS, rendering it inactive (PubMed : 28314590). In apoptotic cells, cleaves SPHK2 which is released from cells and remains enzymatically active extracellularly (PubMed : 20197547).. Isoform Delta. Apoptosis inactive.. Isoform Epsilon. Apoptosis inactive. See full target information CASP1
Category Paths
- Products>Primary Antibodies>Monoclonal Antibodies
- Products>Primary Antibodies>Recombinant Antibodies
- Products>Trial Size Antibodies
Please provide the required information below so that we can quickly source your products.